| 1 |
Development of a Macrophage Activation Based Therapeutic Candidate for Metabolic Dysfunction Associated Steatohepatitis (MASH) and Liver Fibrosis |
| Gene & Nucleic acids |
MASH & Liver Fibrosis |
let-7i-5p microRNA |
Candidate |
NEORNAT Inc. |
RS-2026-25503169 |
|
| 2 |
Developing a bispecific siRNA therapy for dyslipidemia patients with complex symptoms(Csi103) |
| Gene & Nucleic acids |
Dyslipidemia |
PCSK9, APOC3 |
Candidate |
Curigin Co., Ltd. |
RS-2025-02213434 |
|
| 3 |
Adipocyte-Targeted Gene Therapy via Dual FABP4/FABP5 Fat Accumulation Factor Silencing |
| Gene & Nucleic acids |
Obesity, type 2 diabetes |
FABP4/5 |
Candidate |
Cursus Bio Inc. |
RS-2024-00459648 |
|
| 4 |
A study on derivation and optimization of non-clinical candidates for nonalcoholic steatohepatitis gene therapy |
| Gene & Nucleic acids |
NASH |
CR-P1 |
Candidate |
Curogen Technology |
HN21C0805 |
|
| 5 |
Fat-targeting non-viral gene therapeutics for the treatment of obesity and obesity-induced metabolic syndrome |
| Gene & Nucleic acids |
Obesity |
FABP4, FABP5 |
Lead |
Hanyang University |
HN21C0885 |
|